PET PET
  • My Account
  • Subscribe
Become a Friend Donate
  • About Us
    • People
    • Press Office
    • Our History
  • Get Involved
    • Become a Friend of PET
    • Volunteer
    • Campaigns
    • Writing Scheme
    • Partnership and Sponsorship
    • Advertise with Us
  • Donate
    • Become a Friend of PET
  • BioNews
    • News
    • Comment
    • Reviews
    • Elsewhere
    • Topics
    • Glossary
    • Newsletters
  • Events
    • Upcoming Events
    • Previous Events
  • Engagement
    • Policy and Projects
      • Resources
    • Education
  • Jobs & Opportunities
  • Contact Us
  • About Us
    • People
    • Press Office
    • Our History
  • Get Involved
    • Become a Friend of PET
    • Volunteer
    • Campaigns
    • Writing Scheme
    • Partnership and Sponsorship
    • Advertise with Us
  • Donate
    • Become a Friend of PET
  • BioNews
    • News
    • Comment
    • Reviews
    • Elsewhere
    • Topics
    • Glossary
    • Newsletters
  • Events
    • Upcoming Events
    • Previous Events
  • Engagement
    • Policy and Projects
      • Resources
    • Education
  • Jobs & Opportunities
  • Contact Us
  • My Account
  • Subscribe
  • Privacy Statement
  • Advertising Policy
  • Thanks and Acknowledgements
PETBioNewsNews23andMe's genetics screening service sold in violation of regulations, says FDA

BioNews

23andMe's genetics screening service sold in violation of regulations, says FDA

Published 29 November 2013 posted in News and appears in BioNews 733

Author

Ruth Saunders

Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the output from a DNA sequencing machine.
CC BY 4.0
Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the sequencing output from an automated DNA sequencing machine.

The US Food and Drug Administration has ordered 23andMe to 'immediately discontinue' its Personal Genome Service after failing to undergo proper agency approval for its marketing claims...

The US Food and Drug Administration (FDA) has ordered 23andMe to 'immediately discontinue' its Personal Genome Service (PGS) after failing to undergo proper agency approval for its marketing claims.

Alberto Gutierrez, director of the FDA's Center for Devices and Radiological Health, stated in a letter dated 22 November, that 23andMe had failed to address the agency's concerns that the tests could dangerously mislead people about their health.

23andMe first introduced the PGS to the market in 2007, and sells access to an array of information on more than 260 genetic conditions and traits, from a person's carrier status, disease risk, drug response and traits.

The warning letter, addressed to 23andMe co-founder Anne Wojcicki, targeted specific marketing claims about the PGS as a 'first step in prevention' that enables users to 'take steps toward mitigating serious diseases', including heart disease, and breast cancer.

Gutierrez wrote that the 'FDA is concerned about the public health consequences of inaccurate results from the PGS device'.

He mentions 'the potential health consequences that could result from false positive or false negative assessments for high-risk indications such as these'.

'For instance, if the BRCA-related risk assessment for breast or ovarian cancer reports a false positive, it could lead a patient to undergo prophylactic surgery, chemoprevention, intensive screening, or other morbidity-inducing actions'.

Relying on the assessments for drug response could lead customers to 'self-manage' their treatment or abandon treatment altogether, resulting in illness, injury or death, according to the FDA.

The Federal Food, Drug and Cosmetics Act regulates products that are intended to diagnose, mitigate, treat or prevent disease.

The company must provide proof about how accurate its tests are as well as supplying information on the rate of false positives and false negatives.

'Most of these uses have not been classified and thus require premarket approval as FDA has explained to you on numerous occasions', said Gutierrez.

The FDA said it has had 'more than 14 face-to-face and teleconference meetings, hundreds of email exchanges, and dozens of written communications' with 23andMe to discuss compliance with the statute.

'The main purpose of compliance with FDA's regulatory requirements is to ensure that the tests work'.

'However, even after these many interactions with 23andMe, we still do not have any assurance that the firm has analytically or clinically validated the PGS for its intended uses, which have expanded from the uses that the firm identified in its submissions', Gutierrez wrote.

As such, the FDA writes that the applications are considered withdrawn and 23andMe must immediately discontinue marketing until it receives FDA authorisation for its claims.

Failure to take the proper action, the FDA warned, could lead to seizure, injunction, and civil money penalties.

23andMe co-founder Anne Wojcicki responded on the company's blog: 'In July 2012 23andMe submitted its first application for FDA clearance and followed on with another submission at the end of August'.

'We received feedback on those submissions and acknowledge that we are behind schedule with our responses'.

'This is new territory for both 23andMe and the FDA', she wrote.

Related Articles

Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the output from a DNA sequencing machine.
CC BY 4.0
Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the sequencing output from an automated DNA sequencing machine.
News
16 November 2015 • 2 minutes read

FDA warns three US firms over direct-to-consumer genetic testing

by Dr Lone Hørlyck

The US Food and Drug Administration has sent warning letters to three gene-testing companies over the marketing and selling of what it claims are direct-to-consumer gene testing products without its approval...

Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the output from a DNA sequencing machine.
CC BY 4.0
Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the sequencing output from an automated DNA sequencing machine.
Comment
5 May 2015 • 7 minutes read

Eight questions for Anne Wojcicki, CEO and co-founder of 23andMe

by BioNews

For the 800th issue of BioNews, we asked Anne Wojcicki eight questions about personal genomics company 23andMe...

Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the output from a DNA sequencing machine.
CC BY 4.0
Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the sequencing output from an automated DNA sequencing machine.
News
20 February 2015 • 2 minutes read

23andMe gets FDA green light for direct-to-consumer test for rare genetic disorder

by Alice Hazelton

Genetic testing company 23andMe has obtained approval from the US Food and Drug Administration to market a direct-to-consumer genetic test for a rare mutation....

Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the output from a DNA sequencing machine.
CC BY 4.0
Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the sequencing output from an automated DNA sequencing machine.
News
9 January 2015 • 2 minutes read

23andMe partners with Genentech in Parkinson's disease deal

by Rebecca Carr

23andMe, the personal genetics company, has announced an agreement with biotech company Genentech to identify new therapeutic targets for the treatment of Parkinson's disease...

Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the output from a DNA sequencing machine.
CC BY 4.0
Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the sequencing output from an automated DNA sequencing machine.
News
5 December 2014 • 3 minutes read

23andMe launches DNA test in UK

by Arit Udoh

US-based genetic testing company 23andMe has launched its controversial 'personal genome service' in the UK...

Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the output from a DNA sequencing machine.
CC BY 4.0
Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the sequencing output from an automated DNA sequencing machine.
News
7 October 2013 • 3 minutes read

23andMe's 'designer baby' tool patent draws attention

by Dr Sophie Pryor

A US genetics company has been awarded a patent that relates to a DNA analysis service that predicts a baby's traits on the basis of its parents' genes....

Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the output from a DNA sequencing machine.
CC BY 4.0
Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the sequencing output from an automated DNA sequencing machine.
News
17 May 2013 • 2 minutes read

Lung cancer gene test approved as 'companion diagnostic'

by Dr Jamie Heather

The US medicines regulator, the Food and Drug Administration, has approved a genetic test to help doctors select suitable lung cancer patients to be treated with the drug erlotinib...

Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the output from a DNA sequencing machine.
CC BY 4.0
Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the sequencing output from an automated DNA sequencing machine.
News
21 March 2013 • 3 minutes read

Consumer genetics firm 23andMe seeks regulatory approval for disease risk tests

by Ruth Saunders

23andMe, a US-based personal genomics company, has sought regulatory approval from the Food and Drug Administration for seven of its genetic tests....

Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the output from a DNA sequencing machine.
CC BY 4.0
Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the sequencing output from an automated DNA sequencing machine.
News
1 November 2012 • 2 minutes read

Genetic test for sports ability raises concerns in US

by Dr Jay Stone

A US company has launched a mail order genetic test that claims to provide 'athletes and parents of young sports competitors' with information about the user's athletic strengths, what type of training will be most beneficial, and potential injury risks...

Leave a Reply Cancel reply

You must be logged in to post a comment.

« Implantable 'gene circuit' helps obese mice slim down

Data-Label The UK's Leading Supplier Of Medical Labels & Asset Labels

RetiringDentist.co.uk The UK's Leading M&A Company.
easyfundraising
amazon

This month in BioNews

  • Popular
  • Recent
13 June 2022 • 2 minutes read

Drop in diversity of blood stem cells leads to old-age health issues

6 July 2022 • 1 minute read

Frozen embryo transfers linked to high blood pressure in pregnancy

5 July 2022 • 1 minute read

Anorexia in pregnancy linked to increased risk of complications

5 July 2022 • 2 minutes read

Pregnancy after breast cancer treatment does not increase risk of recurrence

5 July 2022 • 1 minute read

No difference between fresh and frozen sperm for IUI

4 July 2022 • 2 minutes read

Shorter IVF protocol reduces risk of OHSS

Subscribe to BioNews and other PET updates for free.

Subscribe
  • Twitter
  • Facebook
  • Instagram
  • LinkedIn
  • YouTube
  • RSS
Wellcome
Website redevelopment supported by Wellcome.

Website by Impact Media Impact Media

  • Privacy Statement
  • Advertising Policy
  • Thanks and Acknowledgements

© 1992 - 2022 Progress Educational Trust. All rights reserved.

Limited company registered in England and Wales no 07405980 • Registered charity no 1139856

Subscribe to BioNews and other PET updates for free.

Subscribe
PET PET

PET is an independent charity that improves choices for people affected by infertility and genetic conditions.

  • Twitter
  • Facebook
  • Instagram
  • LinkedIn
  • YouTube
  • RSS
Wellcome
Website redevelopment supported by Wellcome.

Navigation

  • About Us
  • Get Involved
  • Donate
  • BioNews
  • Events
  • Engagement
  • Jobs & Opportunities
  • Contact Us

BioNews

  • News
  • Comment
  • Reviews
  • Elsewhere
  • Topics
  • Glossary
  • Newsletters

Other

  • My Account
  • Subscribe

Website by Impact Media Impact Media

  • Privacy Statement
  • Advertising Policy
  • Thanks and Acknowledgements

© 1992 - 2022 Progress Educational Trust. All rights reserved.

Limited company registered in England and Wales no 07405980 • Registered charity no 1139856